<div id="readability-page-1"><p>MPM Bioimpact LLC bought a new position in  Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 257,788 shares of the company's stock, valued at approximately $10,902,000. MPM Bioimpact LLC owned 0.41% of Vera Therapeutics as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Vera Therapeutics</strong> alerts:</span></p></div><p>Other large investors have also recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its stake in shares of  Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after buying an additional 1,300,410 shares in the last quarter.  Price T Rowe Associates Inc. MD boosted its position in shares of  Vera Therapeutics by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock valued at $185,107,000 after acquiring an additional 437,940 shares during the last quarter.  FMR LLC lifted its position in  Vera Therapeutics by 9.6% in the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock worth $129,117,000 after buying an additional 267,842 shares during the last quarter.  Vanguard Group Inc. increased its stake in  Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock worth $124,737,000 after purchasing an additional 369,387 shares during the period.  Finally, Paradigm Biocapital Advisors LP raised its holdings in shares of  Vera Therapeutics by 31.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after acquiring an additional 340,488 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors. </p><h2>Vera Therapeutics Stock Performance</h2><p>Shares of VERA stock opened at $21.58 on Wednesday. The firm has a market capitalization of $1.38 billion, a P/E ratio of -8.27 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The company's fifty day moving average price is $23.92 and its two-hundred day moving average price is $34.43. </p><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period in the prior year, the business posted ($0.56) earnings per share.  On average, research analysts anticipate that  Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>VERA has been the topic of a number of research analyst reports. JPMorgan Chase &amp; Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, March 4th. Guggenheim upped their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 27th. Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an &#34;outperform&#34; rating and a $49.00 price target on the stock. HC Wainwright started coverage on shares of Vera Therapeutics in a research report on Monday, May 5th. They set a &#34;buy&#34; rating and a $75.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They issued a &#34;buy&#34; rating and a $58.00 target price on the stock. One investment analyst  has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and a consensus price target of $63.33.</p><p><b>Check Out Our Latest Stock Report on Vera Therapeutics</b></p><h2>About Vera Therapeutics</h2> (Free Report)<p>Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Vera Therapeutics</li><li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li><li>How to Invest in Biotech Stocks</li><li>AppLovin Surges on Earnings: What's Next for This Tech Standout?</li><li>Dividend Payout Ratio Calculator</li><li>U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2><p>Before you consider Vera Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p><p>While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VERA

<p>MPM Bioimpact LLC has acquired a new position in Vera Therapeutics, Inc. (NASDAQ:VERA), purchasing 257,788 shares valued at approximately $10.9 million during the 4th quarter. Other institutional investors, including Avoro Capital Advisors and Price T Rowe Associates, have also increased their stakes in the company. Vera Therapeutics has a market cap of $1.38 billion and reported a quarterly EPS of ($0.81), missing estimates. Analysts have a consensus "Buy" rating for the stock, with a price target averaging $63.33.</p>

MPM Bioimpact LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)